Effect of lamotrigine on carbamazepine epoxide carbamazepine serum concentration ratios in adult patients with epilepsy

被引:15
作者
Gidal, BE
Rutecki, P
Shaw, R
Maly, MM
Collins, DM
Pitterle, ME
机构
[1] UNIV WISCONSIN,DEPT NEUROL,MADISON,WI 53706
[2] CENT WISCONSIN CTR DEV DISABLED,MADISON,WI 53706
[3] UNIV WISCONSIN,COMPREHENS EPILEPSY PROGRAM,MADISON,WI 53706
关键词
carbamazepine; lamotrigine; pharmacokinetics;
D O I
10.1016/S0920-1211(97)00053-3
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Although lamotrigine (LTG) appears to have a low propensity to cause pharmacokinetic interactions with other medications, it has been suggested that LTG may interfere with the elimination of carbamazepine 10,11-epoxide (CBZE), the active metabolite of carbamazepine (CBZ). Evidence for this pharmacokinetic interaction is inconclusive and conflicting, however. We evaluated CBZ apparent oral clearance and the steady-state CBZE/CBZ serum concentration ratios in nine patients (30.8 +/- 7.7 years) with epilepsy prior to and following the initiation of adjunctive treatment with LTG. Overall, CBZ oral clearance was unchanged following the introduction of LTG (5.58 +/- 1.60 vs. 5.81 +/- 1.74 1/h, P = 0.630). Likewise, CBZE to CBZ serum concentration ratios were not significantly different (0.241 +/- 0.082 vs. 0.232 +/- 0.082, P = 0.782). These observations suggest that the addition of LTG did not result in a significant pharmacokinetic interaction involving either CBZ or CBZE. (C) 1997 Elsevier Science B.V.
引用
收藏
页码:207 / 211
页数:5
相关论文
共 15 条
[1]   CLINICAL PHARMACOKINETICS AND PHARMACOLOGICAL EFFECTS OF CARBAMAZEPINE AND CARBAMAZEPINE-10,11-EPOXIDE - AN UPDATE [J].
BERTILSSON, L ;
TOMSON, T .
CLINICAL PHARMACOKINETICS, 1986, 11 (03) :177-198
[2]   CARBAMAZEPINE 10, 11 EPOXIDE CONCENTRATIONS IN EPILEPTICS ON CARBAMAZEPINE ALONE AND IN COMBINATION WITH OTHER ANTI-CONVULSANTS [J].
BRODIE, MJ ;
FORREST, G ;
RAPEPORT, WG .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1983, 16 (06) :747-750
[3]  
CHELBERG RD, 1988, THER DRUG MONIT, V110, P188
[4]  
GRAVES N M, 1991, Epilepsia, V32, P13
[5]   DAILY VARIATIONS IN STEADY-STATE PLASMA-CONCENTRATIONS OF CARBAMAZEPINE AND ITS METABOLITES IN EPILEPTIC CHILDREN [J].
HARTLEY, R ;
FORSYTHE, WI ;
MCLAIN, B ;
NG, PC ;
LUCOCK, MD .
CLINICAL PHARMACOKINETICS, 1991, 20 (03) :237-244
[6]   HUMAN LIVER CARBAMAZEPINE METABOLISM - ROLE OF CYP3A4 AND CYP2C8 IN 10,11-EPOXIDE FORMATION [J].
KERR, BM ;
THUMMEL, KE ;
WURDEN, CJ ;
KLEIN, SM ;
KROETZ, DL ;
GONZALEZ, FJ ;
LEVY, RH .
BIOCHEMICAL PHARMACOLOGY, 1994, 47 (11) :1969-1979
[7]  
Kerr Bradley M., 1995, P529
[8]   PREDICTION OF STEADY-STATE BEHAVIOR OF METABOLITE FROM DOSING OF PARENT DRUG [J].
LANE, EA ;
LEVY, RH .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1980, 69 (05) :610-612
[9]   Optimized high-performance liquid chromatographic method for determination of lamotrigine in serum with concomitant determination of phenytoin, carbamazepine, and carbamazepine epoxide [J].
Lensmeyer, GL ;
Gidal, BE ;
Wiebe, DA .
THERAPEUTIC DRUG MONITORING, 1997, 19 (03) :292-300
[10]   SINGLE-DOSE PHARMACOKINETICS OF CARBAMAZEPINE-10,11-EPOXIDE IN PATIENTS ON LAMOTRIGINE MONOTHERAPY [J].
PISANI, F ;
XIAO, B ;
FAZIO, A ;
SPINA, E ;
PERUCCA, E ;
TOMSON, T .
EPILEPSY RESEARCH, 1994, 19 (03) :245-248